Oculis Holding AG OCS
NASDAQ OCS
$12.17 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Oculis Holding AG (OCS) Non Operating Interest Expenses (2022 - 2026)

Oculis Holding AG (OCS) posted quarterly Non Operating Interest Expenses of -$220921.8 for Q1 2026, up 19.58% year-over-year from -$184741.0 in Q1 2025, and up 26.73% quarter-over-quarter from -$301531.9 in Q4 2025.

Analysis

Oculis Holding AG (OCS) Non Operating Interest Expenses (2022 - 2026) Analysis & Trends

Oculis Holding AG's Non Operating Interest Expenses history runs 5 years deep, the most recent figure standing at -$220921.8 for Q1 2026.

  • In Q1 2026, Non Operating Interest Expenses rose 19.58% year-over-year to -$220921.8; the TTM figure through Mar 2026 stood at -$203.3 million (up 33.44% YoY), while the FY2025 annual figure was -$1.0 million, down 38.32% from the prior year.
  • Non Operating Interest Expenses for Q1 2026 stood at -$220921.8, up from -$301531.9 in the prior quarter.
  • The five-year high for Non Operating Interest Expenses was -$12453.7 in Q3 2023, with the low at -$304.7 million in Q3 2024.
  • The 5-year median for Non Operating Interest Expenses is -$278340.9 (2025), against an average of -$32.2 million.
  • The sharpest annual moves came in 2023 and 2024: Non Operating Interest Expenses jumped 99.34% in 2023, then tumbled 2446652.74% in 2024.
  • Oculis Holding AG's Non Operating Interest Expenses stood at -$1.4 million in 2022, then jumped by 99.01% to -$13528.3 in 2023, then tumbled by 1984.2% to -$281955.9 in 2024, then dropped by 6.94% to -$301531.9 in 2025, then grew by 26.73% to -$220921.8 in 2026.
  • Business Quant data shows OCS's Non Operating Interest Expenses at -$220921.8 in Q1 2026, -$301531.9 in Q4 2025, and -$202.5 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -1.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - 23.78 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Oculis Holding AG 634.75 Mn 345.87 Mn - -390,958.88
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -390,958.88
Mar 31, 2026 -220,921.81
Dec 31, 2025 -301,531.92
Sep 30, 2025 -202,517.74
Jun 30, 2025 -221,043.91
Mar 31, 2025 -274,725.88
Dec 31, 2024 -281,955.90
Sep 30, 2024 -304,710.71
Jun 30, 2024 -96,204.03
Mar 31, 2024 -46,972.97
Dec 31, 2023 -13,528.25
Sep 30, 2023 -12,453.68
Jun 30, 2023 -18,906.98
Mar 31, 2023 -1.38 Mn
Dec 31, 2022 -1.37 Mn
Sep 30, 2022 -1.90 Mn
Jun 30, 2022 -1.73 Mn